yvandenbroek
/
sprookjes
/
Login
Register
TriplyDB
sprookjes
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
2
Q26774440-1BEF5287-C026-43AD-8495-0D6CD6D4739B
Q26774440-1BEF5287-C026-43AD-8495-0D6CD6D4739B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26774440-1BEF5287-C026-43AD-8495-0D6CD6D4739B
Spotlight on ixazomib: potential in the treatment of multiple myeloma
P2860
Q26774440-1BEF5287-C026-43AD-8495-0D6CD6D4739B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26774440-1BEF5287-C026-43AD-8495-0D6CD6D4739B
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
e42880c777ae626bc0bf295bcbc73110ee6123cf
P2860
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.